We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+3.91%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$245M
AUM Growth
+$31M
Cap. Flow
+$33M
Cap. Flow %
13.48%
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49

Top Sells

Rank Stock Value
1
APP icon
Applovin
APP
+$1.14M
2
EXPE icon
Expedia Group
EXPE
+$1.04M
3
KKR icon
KKR & Co
KKR
+$976K
4
CME icon
CME Group
CME
+$974K
5
CPAY icon
Corpay
CPAY
+$948K

Sector Composition

Rank Sector Weight
1 Financials 29.48%
2 Technology 14.86%
3 Healthcare 14.81%
4 Industrials 11.61%
5 Consumer Discretionary 6.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EXEL icon
226
Exelixis
EXEL
$14.2B
$331K 0.14%
9,939
-5,059
-34% -$164K
IONS icon
227
Ionis Pharmaceuticals
IONS
$9.14B
$330K 0.13%
9,448
+1,439
+18% +$53.8K
BNTX icon
228
BioNTech
BNTX
$23.4B
$330K 0.13%
2,897
-534
-16% -$60.9K
LGND icon
229
Ligand Pharmaceuticals
LGND
$5.94B
$330K 0.13%
3,080
-969
-24% -$110K
BPMC
230
DELISTED
Blueprint Medicines
BPMC
$329K 0.13%
3,777
+681
+22% +$62.4K
SWTX
231
DELISTED
SpringWorks Therapeutics
SWTX
$327K 0.13%
9,037
+622
+7% +$21.7K
IOVA icon
232
Iovance Biotherapeutics
IOVA
$2.1B
$325K 0.13%
43,927
+4,858
+12% +$45K
FOLD
233
DELISTED
Amicus Therapeutics
FOLD
$325K 0.13%
34,449
+3,510
+11% +$36.5K
AUPH icon
234
Aurinia Pharmaceuticals
AUPH
$1.92B
$324K 0.13%
36,084
-25,477
-41% -$208K
ADMA icon
235
ADMA Biologics
ADMA
$2.04B
$321K 0.13%
18,728
-11,824
-39% -$222K
LEGN icon
236
Legend Biotech
LEGN
$3.68B
$321K 0.13%
9,852
+2,310
+31% +$95.7K
KRYS icon
237
Krystal Biotech
KRYS
$10.7B
$316K 0.13%
2,016
+214
+12% +$38K
GERN icon
238
Geron
GERN
$930M
$316K 0.13%
89,198
+21,708
+32% +$86.7K
LXRX icon
239
Lexicon Pharmaceuticals
LXRX
$1.04B
$314K 0.13%
425,269
+245,297
+136% +$296K
RARE icon
240
Ultragenyx Pharmaceutical
RARE
$2.56B
$314K 0.13%
7,457
-181
-2% -$8.98K
AXSM icon
241
Axsome Therapeutics
AXSM
$12.1B
$313K 0.13%
3,705
-837
-18% -$77K
NVAX icon
242
Novavax
NVAX
$1.21B
$312K 0.13%
38,765
+16,881
+77% +$163K
VRTX icon
243
Vertex Pharmaceuticals
VRTX
$124B
$303K 0.12%
753
-1,723
-70% -$799K
CRSP icon
244
CRISPR Therapeutics
CRSP
$4.68B
$303K 0.12%
7,702
+2,655
+53% +$125K
ESPR
245
DELISTED
Esperion Therapeutics
ESPR
$302K 0.12%
137,120
+23,942
+21% +$55.9K
AGIO icon
246
Agios Pharmaceuticals
AGIO
$2.14B
$301K 0.12%
9,160
+2,118
+30% +$99.5K
IBRX icon
247
ImmunityBio
IBRX
$7.3B
$294K 0.12%
115,018
+58,911
+105% +$245K
MSDL icon
248
Morgan Stanley Direct Lending Fund
MSDL
$1.29B
$286K 0.12%
13,820
+4,462
+48% +$91.3K
NFE icon
249
New Fortress Energy
NFE
$94.3M
$282K 0.12%
18,636
+11,093
+147% +$115K
YMAB
250
DELISTED
Y-mAbs Therapeutics
YMAB
$280K 0.11%
35,789
+8,457
+31% +$103K

Similar funds

Virtus ETF Advisers's Q4 2024 Portfolio in Review

As of Q4 2024, Virtus ETF Advisers held 511 positions worth $245M, up 15% from $214M the previous quarter. Its ten largest holdings account for 7.3% of the portfolio.

Virtus ETF Advisers deployed $33M of net new capital in Q4 2024, opening 57 new positions and adding to 251 existing holdings. Its largest new stake was State Street SPDR Bloomberg High Yield Bond ETF: 19,660 shares worth $1.88M.

By sector, the portfolio is most concentrated in Financials at 29% of assets, up from 28% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Applovin, an estimated $1.14M trimmed.

  • Virtus ETF Advisers's largest Q4 2024 buy was State Street SPDR Bloomberg High Yield Bond ETF: 19,660 shares worth $1.88M.
  • Virtus ETF Advisers added most to Eagle Point Credit Company in Q4 2024, an estimated $515K increase.
  • Virtus ETF Advisers's biggest Q4 2024 reduction was Applovin, cutting an estimated $1.14M.
  • Virtus ETF Advisers fully exited Expedia Group in Q4 2024, selling an estimated $1.04M.
  • Virtus ETF Advisers's ten largest holdings make up 7.3% of its $245M portfolio in Q4 2024.
  • Virtus ETF Advisers opened 57 new positions and closed 49 in Q4 2024.
  • Virtus ETF Advisers's portfolio value rose 15% quarter-over-quarter to $245M.

Based on Virtus ETF Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.